Stock Code: 002424
Stock Abbreviation: ST Bailing
Announcement No.: 2026-026
Guizhou Bai Ling Pharmaceutical Group Co., Ltd.
Announcement on the 2025 Profit Distribution Plan
The company and all members of the board of directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
I. Deliberation Procedures
(I) Board of Directors Meeting Review
Guizhou Bai Ling Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") held the twenty-fifth meeting of the Sixth Board of Directors on April 27, 2026. The "2025 Profit Distribution Plan" was reviewed and approved by 8 votes in favor, 0 votes against, and 0 abstentions.
(II) This Profit Distribution Plan Needs to be Submitted to the Company's 2025 Shareholders' Meeting for Review.
II. Basic Information on Profit Distribution and Capital Reserve Transfer to Share Capital Plan
(I) Distribution Basis: 2025 Fiscal Year
(II) According to the audit by Tianjian Certified Public Accountants (Special General Partnership), in 2025, the net profit attributable to shareholders of the listed company in the consolidated statements was -104,366,044.91 yuan. As of December 31, 2025, the undistributed profit in the consolidated statements was 1,489,857,929.61 yuan, and the undistributed profit in the parent company's statements was 809,008,931.48 yuan. According to the principle of taking the lower of the parent company and consolidated figures, the profit available for distribution to shareholders in 2025 was 809,008,931.48 yuan. The total share capital is 1,397,598,400 shares.